-
Article
Open AccessEffect of empagliflozin on total myocardial infarction events by type and additional coronary outcomes: insights from the randomized EMPA-REG OUTCOME trial
The effect of empagliflozin, a sodium-glucose-co-transporter-2 inhibitor, on risk for myocardial infarction has not been fully characterized.
-
Article
Open AccessSafety of Empagliflozin: An Individual Participant-Level Data Meta-Analysis from Four Large Trials
Empagliflozin is a sodium-glucose co-transporter-2 inhibitor used to treat type 2 diabetes (T2D) to improve glycemic control, reduce risk of cardiovascular death in patients with T2D, and treat patients with s...
-
Article
Chronic kidney disease and the global public health agenda: an international consensus
Early detection is a key strategy to prevent kidney disease, its progression and related complications, but numerous studies show that awareness of kidney disease at the population level is low. Therefore, inc...
-
Article
Open AccessCorrection: Apolipoprotein A-IV concentrations and cancer in a large cohort of chronic kidney disease patients: results from the GCKD study
-
Article
Open AccessHydrological and geochemical properties of bottom ash landfills
In Switzerland, municipal solid waste incineration bottom ash is deposited in open landfills, which leads to its interaction with rainwater and thus the formation of a polluted leachate. This study attempts to...
-
Article
Open AccessApolipoprotein A-IV concentrations and cancer in a large cohort of chronic kidney disease patients: results from the GCKD study
Chronic kidney disease (CKD) is highly connected to inflammation and oxidative stress. Both favour the development of cancer in CKD patients. Serum apolipoprotein A-IV (apoA-IV) concentrations are influenced b...
-
Article
Diagnosis of cardiovascular disease in patients with chronic kidney disease
Patients with chronic kidney disease (CKD) are at high risk of cardiovascular disease (CVD) and cardiovascular death. Identifying and monitoring cardiovascular complications and hypertension is important for m...
-
Article
Open AccessGuardians For Health: A Practical Approach to Improving Quality of Life and Longevity in People with Type 2 Diabetes
Type 2 diabetes is one of the fastest-growing health emergencies of the twenty-first century, in part due to its association with cardiovascular and renal disease. Successful implementation of evidence-based g...
-
Article
A meta-analysis of GFR slope as a surrogate endpoint for kidney failure
Glomerular filtration rate (GFR) decline is causally associated with kidney failure and is a candidate surrogate endpoint for clinical trials of chronic kidney disease (CKD) progression. Analyses across a dive...
-
Article
Open AccessPrevalence and prognostic impact of chronic kidney disease and anaemia across ACC/AHA precursor and symptomatic heart failure stages
The importance of chronic kidney disease (CKD) and anaemia has not been comprehensively studied in asymptomatic patients at risk for heart failure (HF) versus those with symptomatic HF. We analysed the prevale...
-
Article
KDIGO-Leitlinie zur Behandlung des Diabetes mellitus bei chronischer Nierenerkrankung – Update 2022
Die im November 2022 erschienene Klinische Praxisleitlinie für das Diabetesmanagement bei chronischer Nierenerkrankung („chronic kidney disease“, CKD) der KDIGO(Kidney Disease: Improving Global Outcomes)-Initi...
-
Article
Open AccessClinical characteristics and disease outcomes in non-diabetic chronic kidney disease: retrospective analysis of a US healthcare claims database
The observational, real-world evidence FLIEDER study aimed to describe patient clinical characteristics and investigate clinical outcomes in non-diabetic patients with chronic kidney disease (CKD) using data c...
-
Article
Open AccessCardiovascular outcomes trials: a paradigm shift in the current management of type 2 diabetes
Cardiovascular disease (CVD) is the leading cause of mortality and morbidity in patients with type 2 diabetes (T2D). Historical concerns about cardiovascular (CV) risks associated with certain glucose-lowering...
-
Article
Update zur diastolisch bedingten Herzinsuffizienz
Die neuen Leitlinien der European Society of Cardiology (ESC) zur Herzinsuffizienz von 2021 nehmen eine subtile, klinisch aber relevante Neubewertung der Kategorisierung der Herzinsuffizienz anhand der linksve...
-
Article
Open AccessReport from the CVOT Summit 2021: new cardiovascular, renal, and glycemic outcomes
The 7th Cardiovascular Outcome Trial (CVOT) Summit on Cardiovascular, Renal, and Glycemic Outcomes, was held virtually on November 18–19, 2021. Pursuing the tradition of the previous summits, this reference co...
-
Article
Open AccessConverting from face-to-face to postal follow-up and its effects on participant retention, response rates and errors: lessons from the EQUAL study in the UK
Prospective cohort studies are challenging to deliver, with one of the main difficulties lying in retention of participants. The need to socially distance during the COVID-19 pandemic has added to this challen...
-
Article
Open AccessHerzinsuffizienzprotektion bei Patienten mit Diabetes mellitus Typ 2 durch SGLT2-Inhibitoren – Evidenzlage und mögliche Mechanismen
Hemmstoffe des renalen Natrium-Glukose-Kotransporters 2 („sodium glucose-linked transporter 2“; SGLT2i) scheinen außer der antidiabetischen auch eine kardioprotektive Wirkung zu besitzen; deren Mechanismus ist...
-
Article
Microbially mediated kinetic sulfur isotope fractionation: reactive transport modeling benchmark
Microbially mediated sulfate reduction is a ubiquitous process in many subsurface systems. Isotopic fractionation is characteristic of this anaerobic process, since sulfate-reducing bacteria (SRB) favor the re...
-
Article
Open AccessReport from the CVOT Summit 2020: new cardiovascular and renal outcomes
The 6th Cardiovascular Outcome Trial (CVOT) Summit “Cardiovascular and Renal Outcomes 2020” was the first to be held virtually on October 29–30, 2020. As in previous years, this summit served as reference meet...
-
Article
Open AccessMetabolic syndrome in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a post hoc analyses of the EMPA-REG OUTCOME trial
Patients with type 2 diabetes (T2D) and metabolic syndrome (MetS) are at greater cardiovascular risk than those with T2D without MetS. In the current report we aim to study the characteristics, cardio-renal ou...
